טוען...
Potential COVID-19 infection in patients with severe multiple sclerosis treated with alemtuzumab
BACKGROUND: Management of disease-modifying therapies in Multiple Sclerosis (MS) during the COVID-19 pandemic is a controversial issue. Alemtuzumab is an immunosuppressive drug that induces lymphocytes depletion. In this study, we aimed to evaluate the frequency and severity of COVID-19 in a case se...
שמור ב:
| הוצא לאור ב: | Mult Scler Relat Disord |
|---|---|
| Main Authors: | , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Elsevier B.V.
2020
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7286822/ https://ncbi.nlm.nih.gov/pubmed/32554284 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2020.102297 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|